Sphera Funds Management’s Cytokinetics CYTK Stock Holding History

Sphera Funds Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.52M	Sell	100,000 -159,300	-61%	-$11.4M	1.11%	25
2026 Q1	$17.1M	Buy	+259,300	New	+$16.5M	2.71%	7
2025 Q1	–	Sell	-50,000	Closed	-$2.35M	–	120
2024 Q4	$2.35M	Hold	50,000	–	–	0.43%	75
2024 Q3	$2.64M	Buy	+50,000	New	+$2.79M	0.42%	68
2024 Q1	–	Sell	-35,800	Closed	-$2.99M	–	110
2023 Q4	$2.99M	Sell	35,800 -29,200	-45%	-$1.06M	0.48%	64
2023 Q3	$1.91M	Buy	+65,000	New	+$2.16M	0.35%	67
2017 Q4	–	Sell	-100,000	Closed	-$1.45M	–	138
2017 Q3	$1.45M	Buy	+100,000	New	+$1.37M	0.21%	95
2014 Q2	–	Sell	-131	Closed	-$16K	–	106
2014 Q1	$16K	Buy	+131	New	+$1.19K	﹤0.01%	111

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sphera Funds Management's CYTK Position: Q2 2026 in Review

Sphera Funds Management increased its Cytokinetics (CYTK) stake by 452% in Q2 2026, buying an estimated $12.9M and bringing the position to 219,987 shares worth $18.7M. The position accounts for 2.44% of the portfolio, ranked #10.

Sphera Funds Management first reported a position in CYTK in Q4 2013 and has held it in 26 quarters since. The position peaked at $20.9M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Sphera Funds Management held 219,987 shares of Cytokinetics worth $18.7M as of Q2 2026.
Sphera Funds Management bought 180,170 Cytokinetics shares in Q2 2026, an estimated $12.9M.
Cytokinetics made up 2.44% of Sphera Funds Management's portfolio in Q2 2026, its #10 holding.
Sphera Funds Management first reported a position in Cytokinetics in Q4 2013 and has held it in 26 quarters since.
Sphera Funds Management's Cytokinetics position peaked at $20.9M in Q2 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.